Europe Pulmonary Function Testing Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Europe Pulmonary Function Testing Market Size

• The Europe pulmonary function testing market size was valued at USD 1.05 billion in 2024 and is expected to reach USD 1.61 billion by 2032, at a CAGR of 5.50% during the forecast period
• The market growth is largely fueled by the growing adoption and technological advancements in medical diagnostics, particularly in respiratory and pulmonary care, leading to increased digitalization and integration of healthcare infrastructure across both hospital and ambulatory settings in Europe
• Furthermore, rising demand for accurate, non-invasive, and real-time lung function assessment is establishing Pulmonary Function Testing devices as essential diagnostic tools. These converging factors are accelerating the uptake of Europe Pulmonary Function Testing solutions, thereby significantly boosting the industry's growth

Europe Pulmonary Function Testing Market Analysis

• Pulmonary Function Testing (PFT) systems, which measure lung volume, capacity, flow rates, and gas exchange, are critical diagnostic tools used across European healthcare facilities for the early detection and management of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung diseases
• The demand for pulmonary function testing is steadily increasing in Europe, driven by the growing prevalence of chronic respiratory diseases, rising environmental pollution, and the expanding elderly population. Additionally, the integration of advanced PFT devices with electronic health records (EHRs), portable spirometry solutions, and AI-powered interpretation tools is enhancing diagnostic accuracy and accessibility across outpatient and community settings
• Germany dominated the Europe pulmonary function testing market with the largest revenue share of 28.3% in 2024, supported by its robust healthcare infrastructure, focus on preventive respiratory care, and extensive use of spirometry and plethysmography in clinical and research settings. The country’s strong presence of medical device manufacturers and continuous investment in pulmonary rehabilitation programs are further accelerating market growth
• The U.K. is expected to be the fastest-growing market in Europe, registering a CAGR of 9.1% during the forecast period (2025–2032). Growth is propelled by the high burden of COPD and asthma, government initiatives such as the NHS Long Term Plan promoting early diagnostics, and increased deployment of mobile pulmonary function labs and digital spirometry tools for home-based and remote assessments
• The hardware segment held the largest market share of 54.7% in 2024, driven by the widespread deployment of spirometers, body plethysmographs, and peak flow meters across hospitals and diagnostic labs for accurate respiratory assessment

Report Scope and Europe Pulmonary Function Testing Market Segmentation

Europe Pulmonary Function Testing Market Trends

“Advancements in Digital Integration and Diagnostic Precision”

•  A significant and accelerating trend in the Europe pulmonary function testing (PFT) market is the increasing integration of artificial intelligence (AI), cloud-based connectivity, and mobile health technologies into spirometry and other pulmonary diagnostic systems. These innovations are transforming respiratory care by improving diagnostic accuracy, data accessibility, and patient monitoring across both hospital and home settings
  • For instance, AI-powered pulmonary function analyzers can now automatically interpret complex spirometry patterns and flag abnormal readings, reducing human error and supporting clinicians with faster and more accurate decision-making. Companies like Vitalograph and NDD Medical Technologies are leading the European market with digital spirometry systems that incorporate predictive analytics and real-time feedback
• The adoption of portable and wireless PFT devices, including handheld spirometers and wearable lung function sensors, is growing rapidly. These devices enable point-of-care testing and at-home respiratory monitoring, transmitting data via Bluetooth or cloud platforms to healthcare providers for timely assessment and intervention
• Integration of PFT systems with telemedicine platforms is expanding remote diagnostics and monitoring capabilities, particularly benefiting patients with chronic conditions like COPD and asthma. This approach supports health systems in countries like the U.K., Germany, and the Netherlands in delivering decentralized, patient-centered respiratory care in alignment with their national digital health strategies
• Smartphone-compatible spirometry devices and mobile apps are gaining traction among tech-savvy patients and general practitioners, enabling self-monitoring, automated result interpretation, and secure data sharing with physicians. These tools promote early detection of respiratory decline and improve treatment adherence
• As healthcare providers increasingly adopt connected, AI-enhanced PFT technologies and patients seek more proactive, real-time management of respiratory conditions, the demand for intelligent, digital, and user-centric pulmonary testing solutions is poised to grow significantly across the European market. These innovations are not only advancing clinical outcomes but also improving operational efficiency and long-term patient engagement

Europe Pulmonary Function Testing Market Dynamics

Driver

“Growing Need Due to Rising Respiratory Disease Burden and Digital Health Adoption”

• The increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis, coupled with the growing emphasis on early diagnosis and preventive care, is significantly driving demand for pulmonary function testing systems across Europe
  • For instance, in March 2024, ndd Medical Technologies launched its next-generation spirometry and lung function platform with AI-driven analytics to enhance diagnostic accuracy in both hospital and primary care settings. Such innovations are expected to bolster the Europe Pulmonary Function Testing market growth in the forecast period
• As healthcare systems shift toward decentralized care, pulmonary function testing devices are increasingly adopted in specialty clinics, ambulatory settings, and even home care environments, owing to their non-invasive nature and diagnostic reliability
• Furthermore, the integration of digital health platforms, electronic health records (EHR), and remote respiratory monitoring is making pulmonary function testing a crucial component of modern respiratory care, enabling clinicians to monitor lung health in real-time
• The trend toward compact, portable, and wireless pulmonary testing devices—offering ease of use, rapid results, and telehealth compatibility—is accelerating market adoption in both public and private healthcare sectors. The rise of connected spirometers and digital diagnostic tools is also transforming patient engagement and chronic disease management

Restraint/Challenge

“Data Protection Regulations and High Pulmonary Equipment Costs”

• Despite the benefits of digital pulmonary diagnostic systems, concerns surrounding data security, interoperability, and patient confidentiality under regulations such as GDPR pose significant challenges to broader adoption, particularly in cross-border telemedicine services across Europe
  • For instance, increased scrutiny over cloud-based patient data handling and cybersecurity risks has made healthcare providers more cautious about implementing connected pulmonary function devices in their practices
• To address these concerns, manufacturers must ensure compliance with GDPR, implement end-to-end encryption, and provide secure data storage solutions. Companies like COSMED and Vyaire Medical highlight their adherence to strict data protection protocols in their product offerings
• In addition, the high upfront cost of advanced pulmonary testing systems—particularly those with integrated software, digital interfaces, and remote capabilities—may be a deterrent for smaller clinics and publicly funded hospitals, especially in Eastern and Southern Europe
• While costs are gradually declining due to technological innovation and competitive pressures, pricing remains a key factor influencing adoption rates in resource-constrained settings
• Overcoming these challenges through modular systems, flexible pricing models, and scalable integration with existing digital health infrastructure will be vital for long-term market expansion across Europe

Europe Pulmonary Function Testing Market Scope

The market is segmented on the basis of type, patient type, application, and end user.

• By Type

On the basis of type, the Europe pulmonary function testing market is segmented into hardware, services, and software. The hardware segment held the largest market share of 54.7% in 2024, driven by the widespread deployment of spirometers, body plethysmographs, and peak flow meters across hospitals and diagnostic labs for accurate respiratory assessment.

The software segment is expected to witness the fastest CAGR of 20.1% from 2025 to 2032, owing to the increasing demand for integrated digital platforms that streamline pulmonary data collection, analysis, and cloud-based remote access.

• By Patient Type

On the basis of patient type, the Europe pulmonary function testing market is segmented into pediatric, adult, and geriatric. The adult segment accounted for the largest market share of 48.5% in 2024, due to the high prevalence of respiratory conditions like asthma, COPD, and occupational lung diseases in working-age populations.

The geriatric segment is projected to grow at the highest CAGR of 22.8% during the forecast period, fueled by rising life expectancy, age-related pulmonary decline, and increased focus on early diagnosis and home-based care for elderly patients.

• By Application

On the basis of application, the Europe pulmonary function testing market is segmented into obstructive lung disease and restrictive lung disease. The obstructive lung disease segment held the largest market revenue share of 63.9% in 2024, dominated by conditions like COPD, asthma, and bronchitis, which require continuous pulmonary function testing for management and monitoring.

The restrictive lung disease segment is expected to witness a CAGR of 17.3% from 2025 to 2032, driven by the rising incidence of interstitial lung disease, pulmonary fibrosis, and neuromuscular conditions impairing respiratory function.

• By End User

On the basis of end user, the Europe pulmonary function testing market is segmented into hospitals, specialty clinics, diagnostics laboratories, home care settings, and others. The hospitals segment dominated with a market share of 45.2% in 2024, owing to the availability of full-scale diagnostic infrastructure, advanced testing equipment, and a high volume of inpatient respiratory evaluations.

The home care settings segment is projected to grow at the fastest CAGR of 25.6% from 2025 to 2032, supported by increased adoption of portable spirometry devices and the growing shift toward decentralized, patient-centric respiratory care across Europe.

Europe Pulmonary Function Testing Market Regional Analysis

• Europe dominated the global pulmonary function testing market with the largest revenue share of 38.6% in 2024, driven by the increasing prevalence of chronic respiratory diseases, aging population, and heightened emphasis on early and accurate respiratory diagnostics
• The region's well-developed healthcare infrastructure, strong regulatory focus on pulmonary health, and growing demand for non-invasive diagnostic tools are propelling the adoption of advanced pulmonary function testing (PFT) systems
• Further supporting market expansion is the push for digital healthcare transformation, including integration with electronic health records (EHRs) and remote patient monitoring platforms, positioning PFT systems as essential in both primary and specialized care settings

U.K. Pulmonary Function Testing Market Insight

The U.K. pulmonary function testing market is expected to witness robust growth throughout the forecast period, driven by a strong focus on early detection of respiratory conditions such as asthma and COPD. The National Health Service (NHS) initiatives to improve respiratory diagnostics and expand community-based testing services further support demand. Additionally, the adoption of portable and connected spirometry devices in general practice settings is accelerating due to the country’s digital health transformation agenda.

Germany Pulmonary Function Testing Market Insight

The Germany pulmonary function testing market held a largest revenue share of 28.3% in 2024, supported by its robust healthcare infrastructure, focus on preventive respiratory care, and extensive use of spirometry and plethysmography in clinical and research settings. The country’s strong presence of medical device manufacturers and continuous investment in pulmonary rehabilitation programs are further accelerating market growth. With a rising geriatric population and growing awareness around lung health, especially in post-COVID care, the demand for sophisticated and accurate PFT systems continues to rise. The country also leads in integrating AI-enabled and mobile spirometry tools in clinical practice.

France Pulmonary Function Testing Market Insight

The France pulmonary function testing market is expanding steadily due to increasing respiratory disease burden and government-supported public health campaigns targeting smoking cessation and air quality improvement. French hospitals and specialty clinics are progressively investing in digital respiratory diagnostic systems, and manufacturers are focusing on CE-marked, compliant, and remote-enabled devices to align with national telemedicine strategies.

Italy Pulmonary Function Testing Market Insight

The Italy is seeing rising demand for pulmonary function testing systems, particularly in geriatric and pediatric segments. The country’s emphasis on improving respiratory diagnostics in public healthcare and the post-pandemic focus on long-COVID monitoring are accelerating adoption. Initiatives by regional health authorities to decentralize respiratory care to primary settings have also increased the use of portable spirometers and integrated software platforms.

Europe Pulmonary Function Testing Market Share

The Europe pulmonary function testing industry is primarily led by well-established companies, including:

• VYAIRE MEDICAL, INC. (U.S.)
• Teleflex Incorporated (U.S.)
• CAIRE, Inc. (U.S.)
• COSMED srl (Italy)
• Schiller AG (Switzerland)
• Ganshorn Medizin Electronic GmbH (Germany)
• ndd Medical Technologies (Switzerland)
• KoKo PFT (U.K./Germany)
• GERATHERM MEDICAL AG (Germany)
• ECO MEDICS (Switzerland)
• SIBEL, S.A.U. (Spain)
• Clarity Medical (Ireland)
• Data Sciences International (U.S.)
• MEC (Belgium)
• Scireq (Canada)
• MEDLINE (U.S.)
• Recorders and Medicare Systems (U.K.)
• VITALOGRAPH (U.K.)
• medical equipment europe GMBH (Germany)
• CHEST M.I., Inc. (U.S.)
• CONTEC MEDICAL SYSTEMS CO., LTD (China)

Latest Developments in Europe Pulmonary Function Testing Market

• In April 2023, Cardioline S.P.A. (Italy) joined the PariSanté Campus initiative—aimed at accelerating digital health innovation in Europe including AI‑powered ECG diagnostics and improved cardiovascular risk assessment
• In July 2025, Royal Philips officially launched its Philips ECG AI Marketplace, with Anumana’s FDA‑cleared LEF (Low Ejection Fraction) algorithm as its first third‑party solution—enabling hospitals across Europe and the U.S. to integrate AI‑based ECG diagnostics into existing workflows for faster detection and treatment of heart failure risk
• In April 2024, Clario's acquisition of ArtiQ enhances its Respiratory Solutions portfolio by integrating advanced AI capabilities. This strategic move combines Clario's expertise with ArtiQ’s innovative technology to improve test quality and accelerate data processing in clinical trials. The acquisition, alongside Inofab Health, solidifies Clario's leadership in respiratory care and broadens its AI-driven clinical solutions
• In September 2023, PulmOne has launched the MiniBox+ in China, showcasing it to pulmonologists at the 2023 Annual Congress of the Chinese Thoracic Society (CTS) through our distributor HTDK. The introduction was met with great enthusiasm from attendees. Check out the exciting video highlights from the event
• In May 2023, Geratherm Medical AG, was honored as a "hidden champion" by the State Development Corporation of Thuringia (LEG). The recognition highlights the company's significant role in medical technology and its global market presence. Board member Christian Frick expressed gratitude for the accolade, noting the company's innovation in medical diagnostics, lung function measurement, stroke prevention, and incubator systems, which positions it well for future growth
• In May 2023, Vitalograph, a leader in respiratory diagnostics, has expanded its portfolio with the introduction of the Vitalograph tremoflo C-100 Oscillometer at the ATS International Conference. Developed in partnership with Thorasys, this innovative device detects small airway impairment through simple tidal breathing, enhancing the diagnosis of asthma and COPD. The tremoflo C-100 integrates with the Vitalograph Spirotrac platform, offering a comprehensive view of respiratory health and supporting accurate, portable testing in various settings
• In April 2023, Ingmar Medical introduced RespiSim Software Version 4.3 a key advancement, including improved scenario import/export, reduced simulation lag, and enhanced platform stability. These updates significantly elevate usability and performance, making it a vital tool for respiratory therapy education and training

SKU-72774